Abstract:
An attempt was made in the present study to explore the structural requirements of known estrogen
receptor (ER) modulators for biological activity using pharmacoinformatics approaches to elucidate
critical functionalities for new, potent and less toxic chemical agents for successful application in
estrogen therapy. For this purpose a group of non-steroidal ligands, 7-thiabicyclo[2.2.1]hept-2-ene-7-
oxide derivatives were collected from the literature to perform quantitative structure-activity relationship
(QSAR), pharmacophore and molecular docking studies. The 2D QSAR models (R2
α = 0.857, seα = 0.370,
Q2
α = 0.848, R2
pred-α = 0.675, spα = 0.537; R2
β = 0.874, seβ = 0.261, Q2
β = 0.859, R2
pred-β = 0.659, spβ =
0.408) explained that hydrophobicity and molar refractivity were crucial for binding affinity in both α-
and β-subtypes. The space modeling study (R2
α = 0.955, seα = 1.311, Q2
α = 0.932, R2
pred-α = 0.737, spα =
0.497; R2
β = 0.885, seβ = 1.328, Q2
β = 0.878, R2
pred-β = 0.769, spβ = 0.336) revealed the importance of HB
donor and hydrophobic features for both subtypes, whereas, HB acceptor and aromatic ring were critical
for α- and β-subtypes respectively. The functionalities developed in the QSAR and pharmacophore
studies were substantiated by molecular docking which provided the preferred orientation of ligands for
effective interaction at the active site cavity.
